Carl Zeiss Meditec Shares Trail Far Behind Surging Small-Cap Peers

Carl Zeiss Meditec shares fall ~37% YTD, defying a strong German small-cap rally. Technicals show deep weakness as sector rotation to chips & defense leaves medtech behind.

As Germany's small-cap equities staged a remarkable rally through the early months of 2026, shares of Carl Zeiss Meditec moved decisively in the opposite direction. The medical technology group finds itself among the worst performers in the segment, having declined by approximately 37% since the start of the year.

A Stark Divergence in Performance

The scale of underperformance becomes evident when comparing its trajectory to other German small-cap stocks. Aixtron has seen its market valuation nearly double this year, posting a gain of 92%, while MorphoSys has delivered returns just slightly below that figure. Even Bechtle, which is also classified as an underperformer with a year-to-date loss of around 32%, stands five percentage points ahead of Carl Zeiss Meditec.

Technical analysis underscores the persistent weakness. The equity recently closed at 24.86 euros, a level roughly 37% below its 200-day moving average. Its 52-week high of 65.50 euros now lies more than 60% away—a price point that appears unlikely to be revisited in the foreseeable future.

Missing the Rotation Wave

A significant factor behind this lagging performance is the sector rotation that characterized the first quarter of 2026. Market leadership was decisively captured by semiconductor and defense stocks, leaving the medical technology sector largely overlooked. Carl Zeiss Meditec failed to benefit from the broad surge in risk appetite that propelled other areas of the market.

Investors may gain some insight into shifting sentiment on April 23rd, when SAP is scheduled to release its quarterly figures. As a key barometer for the German technology sector, SAP's results could provide short-term directional cues for related stocks. However, given the fundamental challenges facing Carl Zeiss Meditec, it remains questionable whether any positive momentum would be sufficient to reverse the prevailing selling pressure.